我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

改善心肌原位干细胞治疗心肌梗死疗效的策略

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第6期
页码:
726-730
栏目:
综述
出版日期:
2013-11-25

文章信息/Info

Title:
Strategies for improving effectiveness of cardiac stem cell therapy for myocardial infarction
作者:
田 磊王长谦
(上海交通大学医学院附属第九人民医院心内科,上海 200011)
Author(s):
TIAN Lei WANG Chang qian
(Department of Cardiology, Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200011, China)
关键词:
心肌原位干细胞心肌梗死疗效策略
Keywords:
cardiac stem cell myocardial infarction effectiveness strategy
分类号:
R542.22
DOI:
-
文献标识码:
A
摘要:
虽然药物治疗、心脏介入手术及心脏搭桥手术等治疗心肌梗死(MI)的方法在不断改进,但MI仍然是全球范围内人类的主要死因。干细胞治疗作为一种可以替代梗死心肌细胞的治疗方法,已经进行了临床试验,但其改善心功能的效果十分有限。目前关于改善心肌原位干细胞(CSCs)治疗MI疗效的策略主要有:①选择更合适的CSCs;②用基因工程的方法处理CSCs;③采用不同导入CSCs的方法。本文就以上3种主要策略的最新研究进展、以CSCs治疗MI的机制以及目前存在的问题作一综述。
Abstract:
Despite recent advances in medical therapy, reperfusion strategies, implantable cardioverterdefibrillators and cardiac assistance devices, myocardial infarction (MI) remains a frequent cause of morbidity and mortality worldwide. Stem cell therapy has been introduced as a new treatment modality to regenerate lost cardiomyocytes. Cardiac stem cell (CSC) is one of the most hopeful types of stem cells to treat ischemic heart diseases. Although obvious improvement of left ventricular function has been reported in animal models, there are only moderate beneficial achievements clinically in myocardial regeneration. To date, strategies for improving effectiveness of cardiac stem cell therapy for myocardial infarction mainly include: 1) identification of the suitable CSCs; 2) gene engineering preconditioning of CSCs; and 3) development of methods to deliver CSCs into myocardium. Stem cell research and therapy will continue to provide novel approaches to diagnoses, therapies and tissue regeneration. In terms of the character of CSC and the mechanism of CSC therapy for MI, we review the recent developments of strategies to improve CSC therapy for MI and highlight the future goals and challenges that must be overcome.

参考文献/References

[1]Borchardt T,Braun T.Cardiovascular regeneration in nonmammalian model systems:what are the differences between newts and man?[J].Thromb haemost,2007,98(2):311-318.
[2]Poss KD. Getting to the heart of regeneration in zebrafish[J].Semin Cell Dev Biol,2007,18(1):36-45.
[3]Mohsin S,Siddiqi S,Collins B,et al.Empowering adult stem cells for myocardial regeneration[J].Circ Res,2011,109(12):1415-1428.
[4]Bolli R,Chugh AR,D’Amario D,et al.Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO):initial results of a randomised phase 1 trial[J].Lancet,2011,378(9806):1847-1857.
[5]Makkar RR,Smith RR,Cheng K,et al.Intracoronary cardiosphere derived cells for heart regeneration after myocardial infarction (CADUCEUS):a prospective,randomised phase 1 trial[J].Lancet,2012,379(9819):895-904.
[6]Choi SH,Jung SY,Kwon SM,et al.Perspectives on stem cell therapy for cardiac regeneration. Advances and challenges[J].Circ J,76(6):1307-1312.
[7]HooverPlow J,Gong Y.Challenges for heart disease stem cell therapy[J].Vasc Health Risk Manag,2012,8:99-113.
[8]Steinhauser ML,Lee RT.Regeneration of the heart[J]. EMBO Mol Med, 2011, 3(12):701-712.
[9]Beltrami AP, Barlucchi L,Torella D,et al.Adult cardiac stem cells are multipotent and support myocardial regeneration[J].Cell,2003,114(6):763-776.
[10]Bergmann O,Bhardwaj RD,Bernard S,et al.Evidence for cardiomyocyte renewal in humans[J].Science,2009,324(5923):98-102.
[11]Tang J,Wang J,Kong X,et al.Vascular endothelial growth factor promotes cardiac stem cell migration via the PI3K/Akt pathway[J].Exp Cell Res,2009,315(20):3521-3531.
[12]Bocchi L,Savi M,Graiani G,et al.Growth factor induced mobilization of cardiac progenitor cells reduces the risk of arrhythmias, in a rat model of chronic myocardial infarction[J].PLoS One,2011,6(3):e17750.
[13]Kuang D,Zhao X,Xiao G,et al.Stem cell factor/ckit signaling mediated cardiac stem cell migration via activation of p38 MAPK[J].Basic Res Cardiol,2008,103(3):265-273.
[14]Wan J,Deng Y,Guo J,et al.Hyperhomocysteinemia inhibited cardiac stem cell homing into the periinfarcted area post myocardial infarction in rats[J].Exp Mol Pathol,2011,91(1):411-418.
[15]Tang YL,Zhu W,Cheng M,et al.Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression[J].Circ Res,2009,104(10):1209-1216.
[16]Iwakura T,Mohri T,Hamatani T,et al.STAT3/Pim1 signaling pathway plays a crucial role in endothelial differentiation of cardiac resident Sca1+ cells both in vitro and in vivo[J].J Mol Cell Cardiol,2011,51(2):207-214.
[17]Loffredo FS,Steinhauser ML,Gannon J,et al.Bone marrowderived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair[J]. Cell Stem Cell,2011,8(4):389-398.
[18]Chimenti I,Smith RR,Li TS,et al.Relative roles of direct regeneration versus paracrine effects of human cardiospherederived cells transplanted into infarcted mice[J].Circ Res,2010,106(5):971-980.
[19]Lu HH,Li YF,Sheng ZQ,et al.Preconditioning of stem cells for the treatment of myocardial infarction[J].Chin Med J (Engl),2012,125(2):378-384.
[20]ItzhakiAlfia A,Leor J,Raanani E,et al.Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells[J].Circulation,2009,120(25):2559-2566.
[21]Simpson DL,Mishra R,Sharma S,et al.A strong regenerative ability of cardiac stem cells derived from neonatal hearts[J].Circulation,2012, 126(11 Suppl 1):S46-S53.
[22]Takamiya M,Haider KH,Ashraf M.Identification and characterization of a novel multipotent subpopulation of Sca-1(+) cardiac progenitor cells for myocardial regeneration[J].PLoS One,2011,6(9):e25265.
[23]D’Amario D,CabralDaSilva MC,Zheng H,et al.Insulinlike growth factor1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration[J].Circ Res,2011,108(12):1467-1481.
[24]Lan F,Liu J,Narsinh KH,et al.Safe genetic modification of cardiac stem cells using a sitespecific integration technique[J].Circulation,2012,126(11 Suppl 1):S20-S28.
[25]Barzelay A,Hochhauser E,EntinMeer M,et al.Islet-1 gene delivery improves myocardial performance after experimental infarction[J].Atherosclerosis,2012,223(2):284-290.
[26]
[26]Hu S,Huang M,Nguyen PK,et al.Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation[J].Circulation,2011,124(11 Suppl):S27-S34.
[27]Fischer KM,Din S,Gude N,et al.Cardiac progenitor cell commitment is inhibited by nuclear Akt expression[J].Circ Res,2011,108(8):960-970.
[28]Bauer M,Kang L,Qiu Y,et al.Adult cardiac progenitor cell aggregates exhibit survival benefit both in vitro and in vivo[J].PLoS One,2012,7(11):e50491.
[29]Habib M,ShapiraSchweitzer K,Caspi O,et al.A combined cell therapy and insitu tissueengineering approach for myocardial repair[J].Biomaterials,2011, 32(30):7514-7523.
[30]PadinIruegas ME,Misao Y,Davis ME,et al.Cardiac progenitor cells and biotinylated insulinlike growth factor1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction[J].Circulation,2009,120(10):876-887.
[31]Hamdi H,PlanatBenard V,Bel A,et al.Epicardial adipose stem cell sheets results in greater postinfarction survival than intramyocardial injections[J].Cardiovasc Res,2011,91(3):483-491.
[32]Williams AR, Hatzistergos KE,Addicott B,et al.Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction[J].Circulation,2013,127(2):213-223.
[33]Williams AR,Hatzistergos KE,Addicott B,et al.Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction[J].Circulation,2013,127(2):213-223.
[34]Brunt KR,Weisel RD,Li RK.Stem cells and regenerative medicinefuture perspectives[J].Can J Physiol Pharmacol,2012,90(3):327-335.

备注/Memo

备注/Memo:
收稿日期:2013-04-14.通讯作者:王长谦,教授,主要从事动脉粥样硬化及冠心病防治研究 Email:changqianwang@hotmail.com 作者简介:田磊,硕士生 Email:czyxy2007@163.com
更新日期/Last Update: 2013-11-20